The Effect of Inluowei EpiCor Compound Powder on Adjunctive Efficacy and Dynamic Changes of Enteric Microflora in Moderate to Severe Acaroid Hypersperstive Rhinitis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500098169

Enrollment

Unknown

Registered

2025-03-04

Start date

2024-03-09

Completion date

Unknown

Last updated

2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis

Interventions

Test group :The experimental group was given EpiCor yeast-probiotic compound powder

control group:the control group was placebo control.

Eligibility

Sex/Gender

All

Age

3 Years to 6 Years

Inclusion criteria

Inclusion criteria: (1) Pre-school children aged 3-6 years; (2) Confirmed moderate to severe persistent allergic rhinitis; (3) Mite allergen test was positive;

Exclusion criteria

Exclusion criteria: (1) mild allergic rhinitis; (2) Have uncontrolled or severe asthma; (3) suffering from serious cardiovascular and cerebrovascular diseases, acute and chronic infectious diseases, autoimmune or immunodeficiency diseases, malignant tumors and other diseases; (4) Patients with severe mental illness or difficult to cooperate with treatment. (5) Discontinuation of treatment during the study.

Design outcomes

Primary

Measure	Time frame
Allergic rhinitis symptom score;Fecal flora composition and structure;Metabolite;	—

Secondary

Measure	Time frame
cytokine;dermatophagoides farinae allergen specific IgE;dermatophagoides pteronyssinus allergen specific IgE;Total serum IgE;	—

Countries

China

Contacts

Public ContactLumin Chen

Fujian Children's Hospital

fbk2011@163.com+86 591 8611 2223

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026